Labcorp Perspectives: Optimizing biomarker testing in advanced NSCLC: Insights on comprehensive genomic profiling (CGP)

In the latest episode of Labcorp Perspectives: Oncology, Dr. Rebecca Ann Previs and Dr. Kyle Strickland, directors of medical affairs at Labcorp Oncology, delve into the significant advantages of comprehensive genomic profiling (CGP) over single-gene testing in patients with advanced non-small cell lung cancer (NSCLC). This study, using OmniSeq® INSIGHT, showed that CGP enables that patients with NSCLC to be tested for all recommended biomarkers at once, providing the best chance of identifying effective treatment options. Traditional single-gene tests may miss important biomarkers and can use up valuable tumor tissue, limiting further testing options and potentially delaying treatment. By identifying actionable mutations in one comprehensive test, CGP enables effective targeted therapy options, particularly in the context of evolving cancer care strategies.